CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

Right arrow Help viewing high resolution images
Right arrow Return to article


Fig. 2. Src kinase inhibitor PP1 inhibits MAPK activation by IGF-I. Proliferating 3T3-L1 cells were treated with 10 µM PP1 for 30 min prior to stimulation with 10 nM IGF-I (solid bars) for 5 min or no stimulation (open bars). Proteins in cell lysates were separated by SDS-PAGE and analyzed by Western blotting using phospho-MAPK antibodies (top panel) followed by ERK1/2 MAPK antibodies (not shown). Below the blot, densitometry of the phospho-MAPK bands, corrected for total MAPK content. This experiment was repeated two more times with the same results.





Right arrow Return to article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation